+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Disopyramide Market - Global Forecast 2026-2032- Product Image
Disopyramide Market - Global Forecast 2026-2032- Product Image
New

Disopyramide Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083041
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The disopyramide market is evolving rapidly as clinical practice, regulatory pressures, and supply chain strategies redefine the agent’s positioning for cardiac rhythm management. Senior decision-makers navigating complex procurement, safety, and operational priorities will benefit from a nuanced understanding of this market’s drivers and challenges.

Market Snapshot: Disopyramide Market Size and Growth

In 2025, the global disopyramide market reached USD 270.27 million and is forecasted to grow to USD 282.43 million in 2026, rising at a CAGR of 5.03% and projected to reach USD 381.26 million by 2032. Growth reflects evolving treatment pathways, continued clinical relevance, and new pressures from supply chain and regulatory adjustments.

Scope & Segmentation

This report provides a comprehensive analysis of the disopyramide market, focusing on segmentation across clinical, operational, and geographic dimensions:

  • Dosage Forms: Capsules, tablets, injections (differentiated by intramuscular and intravenous forms), each with unique clinical indications and logistical requirements.
  • Care Settings: Hospitals (private and public), clinics, and home healthcare, reflecting diverse procurement processes and patient mixes.
  • Distribution Channels: Hospital pharmacies (segmented by public and private), online pharmacies (manufacturer-direct, third-party platforms), and retail (chain and independent) pharmacies.
  • Regions: Americas, Europe Middle East & Africa, Asia-Pacific, each shaped by distinct healthcare infrastructure, regulatory frameworks, and prevalence of arrhythmia management modalities.
  • Key Technologies: Remote monitoring, digital patient management, and integration of automated supply chain and pharmacovigilance systems.

Key Takeaways for Senior Decision-Makers

  • Disopyramide’s clinical profile and real-world safety requirements maintain its relevance in select patient populations, but its use is being re-evaluated alongside advancing device-based and pharmacologic therapies.
  • Segment-specific requirements, such as sterile handling for intravenous formulations, directly impact production planning and inventory management, making supplier and distributor coordination critical.
  • Healthcare consolidation and changes to reimbursement models are altering buying dynamics and manufacturer margins for legacy pharmaceuticals, including antiarrhythmics.
  • Sophisticated risk stratification and increased monitoring are influencing prescribing behaviors, driving the need for robust provider education and patient stewardship programs.
  • Digital health integration for dosing and monitoring is expanding opportunities for safer outpatient management, but raises expectations for clinical support and technical resources from suppliers.
  • Regional contrasts in regulatory timelines and reimbursement strategies necessitate differentiated commercialization and compliance approaches to maintain reliable access and minimize supply disruptions.

Tariff Impact on Supply Chain Resilience and Pricing

Tariff adjustments in the United States in 2025 have introduced new complexities into the disopyramide supply chain. Increased costs for imported ingredients and specialty excipients have influenced manufacturing sourcing decisions and operational efficiency. Producers are responding with strategies such as dual sourcing, nearshoring, and tighter inventory control. Distributors and hospital pharmacies are adapting by diversifying procurement and expanding safety stocks to maintain therapeutic continuity. These dynamics highlight the need for proactive risk assessments and transparent supplier relationships throughout the chain.

Methodology & Data Sources

This analysis draws on peer-reviewed clinical studies, regulatory guidelines, interviews with clinicians and procurement leaders, and supply chain incident data. Triangulation of primary and secondary sources ensures a robust synthesis of market, clinical, and operational realities. The methodology section and appendices detail inclusion criteria and interview protocols for full transparency.

Why This Report Matters

  • Enables senior leadership to anticipate and plan for market shifts due to clinical, regulatory, and supply-side disruption.
  • Delivers actionable insight into optimizing procurement, risk management, and safety strategies across evolving care models.
  • Equips commercial, clinical, and operational teams with detailed segmentation and region-specific intelligence to support evidence-based decisions.

Conclusion

The disopyramide market requires coordinated, evidence-driven actions across supply, safety, and commercial functions to sustain access and optimize therapeutic outcomes. Stakeholders who align strategy to clinical needs, regulatory requirements, and evolving supply realities are positioned to drive sustainable value and patient care leadership.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Disopyramide Market, by Dosage Form
8.1. Capsules
8.2. Injections
8.2.1. Intramuscular Injections
8.2.2. Intravenous Injections
8.3. Tablets
9. Disopyramide Market, by End User
9.1. Clinics
9.2. Home Healthcare Settings
9.3. Hospitals
9.3.1. Private Hospitals
9.3.2. Public Hospitals
10. Disopyramide Market, by Distribution Channel
10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies
11. Disopyramide Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. Disopyramide Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Disopyramide Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States Disopyramide Market
15. China Disopyramide Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. Apotex Inc.
16.6. AstraZeneca plc
16.7. Aurobindo Pharma Limited
16.8. Cipla Limited
16.9. Dr. Reddy's Laboratories Limited
16.10. Dr. Reddy's Labratories Inc.
16.11. Endo International plc
16.12. Merck & Co., Inc.
16.13. Novartis Group
16.14. Pfizer Inc.
16.15. Sandoz International GmbH
16.16. Sanofi S.A.
16.17. Sun Pharmaceutical Industries Limited
16.18. Teva Pharmaceutical Industries Limited
16.19. The Bristol-Myers Squibb Company
16.20. Viatris Inc.
16.21. Viatris Inc.
16.22. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL DISOPYRAMIDE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DISOPYRAMIDE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DISOPYRAMIDE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DISOPYRAMIDE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DISOPYRAMIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DISOPYRAMIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES DISOPYRAMIDE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA DISOPYRAMIDE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DISOPYRAMIDE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DISOPYRAMIDE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DISOPYRAMIDE MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DISOPYRAMIDE MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INTRAMUSCULAR INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INTRAMUSCULAR INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INTRAMUSCULAR INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DISOPYRAMIDE MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DISOPYRAMIDE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DISOPYRAMIDE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DISOPYRAMIDE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DISOPYRAMIDE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DISOPYRAMIDE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DISOPYRAMIDE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DISOPYRAMIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DISOPYRAMIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DISOPYRAMIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DISOPYRAMIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DISOPYRAMIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DISOPYRAMIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DISOPYRAMIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DISOPYRAMIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DISOPYRAMIDE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DISOPYRAMIDE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DISOPYRAMIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DISOPYRAMIDE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DISOPYRAMIDE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DISOPYRAMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. AMERICAS DISOPYRAMIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 48. AMERICAS DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 49. AMERICAS DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 53. NORTH AMERICA DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. NORTH AMERICA DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 55. NORTH AMERICA DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. LATIN AMERICA DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. LATIN AMERICA DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 61. LATIN AMERICA DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA DISOPYRAMIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. EUROPE DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. EUROPE DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 73. EUROPE DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 74. EUROPE DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. EUROPE DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 76. EUROPE DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. MIDDLE EAST DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 79. MIDDLE EAST DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. AFRICA DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. AFRICA DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 85. AFRICA DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 86. AFRICA DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. AFRICA DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 88. AFRICA DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL DISOPYRAMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. ASEAN DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. ASEAN DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 98. ASEAN DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 99. ASEAN DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. ASEAN DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 101. ASEAN DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. GCC DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GCC DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 104. GCC DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 105. GCC DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. GCC DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 107. GCC DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. EUROPEAN UNION DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. EUROPEAN UNION DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 110. EUROPEAN UNION DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. BRICS DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. BRICS DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 116. BRICS DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 117. BRICS DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. BRICS DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 119. BRICS DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. G7 DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. G7 DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 122. G7 DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 123. G7 DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. G7 DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 125. G7 DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. NATO DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. NATO DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 128. NATO DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 129. NATO DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. NATO DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 131. NATO DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL DISOPYRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. UNITED STATES DISOPYRAMIDE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 134. UNITED STATES DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 135. UNITED STATES DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. CHINA DISOPYRAMIDE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 140. CHINA DISOPYRAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 141. CHINA DISOPYRAMIDE MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
TABLE 142. CHINA DISOPYRAMIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. CHINA DISOPYRAMIDE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 144. CHINA DISOPYRAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Disopyramide market report include:
  • Apotex Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Dr. Reddy's Labratories Inc.
  • Endo International plc
  • Merck & Co., Inc.
  • Novartis Group
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • The Bristol-Myers Squibb Company
  • Viatris Inc.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 282.43 Million
Forecasted Market Value ( USD ) by 2032 $ 381.26 Million
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Disopyramide (CAS 3737-09-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Disopyramide (CAS 3737-09-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Disopyramide Phosphate (CAS 22059-60-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Disopyramide Phosphate (CAS 22059-60-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2025 - Product Image

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Clonidine Market - Global Forecast 2026-2032 - Product Image

Clonidine Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Injection Diltiazem Hydrochloride Market - Global Forecast 2025-2030 - Product Image

Injection Diltiazem Hydrochloride Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From

About the Market

Disopyramide is a cardiovascular drug used to treat abnormal heart rhythms. It is a class I antiarrhythmic drug, meaning it works by blocking sodium channels in the heart, slowing the heart rate and stabilizing the rhythm. It is used to treat ventricular tachycardia, ventricular fibrillation, and atrial fibrillation. It is also used to treat supraventricular tachycardia, a condition in which the heart beats too quickly. Disopyramide is available in both oral and intravenous forms. Common side effects of disopyramide include dizziness, drowsiness, nausea, and constipation. It can also cause low blood pressure, dry mouth, and blurred vision. It is important to note that disopyramide can interact with other medications, so it is important to discuss all medications with a doctor before taking disopyramide. The disopyramide market is a competitive one, with many companies offering their own versions of the drug. Some of these companies include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.